Please login to the form below

Not currently logged in
Email:
Password:

Roche signs exclusive distribution deal

Roche has signed an exclusive distribution deal with DxS for two cancer tests designed to help assist doctors in identifying suitable patients for treatment
Roche has signed an exclusive distribution deal with DxS for two cancer tests designed to help assist doctors in identifying suitable patients for treatment.

The K-RAS test will aid in the selection of suitable colorectal cancer patients for treatment, whereas the EGFR 29 test will aid doctors in selecting lung cancer patients suitable for treatment with some inhibitor therapies.

The European Commission recently granted a conditional marketing authorisation for a potential treatment for patients with non-mutated K-RAS genes who do not respond to standard chemotherapy regimens.

Daniel O'Day, president and CEO of Roche Molecular Diagnostics said: "There is a growing demand for tests to indicate disease prognosis and identify patient groups more likely to benefit from a particular drug."

Roche has been granted exclusive worldwide distribution rights for the K-RAS test, and exclusive distribution rights inall global markets except the US, Canada, Mexico and Hong Kong for the EGFR 29 test. Both tests have CE Mark certification in Europe.

"Not only does it [the distribution agreement] enable us to meet the growing demand for these tests, but it also gives doctors and patients access to standardised test results that provide further information to enhance treatment decisions," said Dr Stephen Little, CEO of DxS.

2nd June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics